Edith de Boer is the HR Director for Zimmer Biomet in Australia and New Zealand. Her career originally was in telecommunications and consulting in Europe. After leaving The Netherlands, Edith worked into the Australian medical research industry, before moving into a human resources role at Zimmer Biomet. Edith spoke to Australian Health Journal about her role and the organisation.
Promoting medical technology as an industry is important for Zimmer Biomet. The organisation runs a program called “Your future in STEM” helping girls at high school children consider STEM as a career, through to career professionals in the “Women-Inspired Network” or WIN as it’s commonly referred to. In clinical professions, the Zimmer Biomet “Women in Orthopaedics” program for female surgeons, acts in an advocate and support role.
Collaboration and work mindset of one team is very important for the organisation, as well as employees having a sense of belonging and being included. So whilst, talent can be difficult to find in the current market, Zimmer Biomet staff are together taking a journey of change that’s occurring across the industry.
Upbeat Edith’s energy is refreshing! Anyone looking to enter the medical technology industry and specifically the humans resources role can make a difference to people’s lives. Her advice? Be creative, work hard and have a growth mindset.
You Might also like
-
National Cancer Plan activates Australian Comprehensive Cancer Network
The landscape of cancer care in Australia is set to transform with the Australian Government launch in May 2024 of the Australian Comprehensive Cancer Network (ACCN) at the Innovations Showcase event, hosted by Cancer Australia in Sydney, Australia.
The ACCN is a nationally integrated system of cancer care, aimed at enhancing patient experiences and outcomes through coordinated and equitable access, by linking to comprehensive cancer services across Australia. Anchored by Comprehensive Cancer Centres (CCCs), the ACCN strives to deliver evidence-driven prevention, diagnosis, treatment, and support to all Australians affected by cancer.
-
Foundation outlines breast cancer research strategy
Australian Health Journal met with Associate Professor Cleola Anderiesz, CEO of the National Breast Cancer Foundation to hear of the new 5 year Pink Horizon research strategy. Those with lived experience of breast cancer, along with researchers, clinicians, and other funding organisations, have contributed to the development of the foundation’s new five-year Pink Horizon research strategy. This ambitious plan aims to invest $125 million to accelerate research efforts towards the vision of ending deaths from breast cancer.
-
Strategic research investments for health and prosperity
The CEO of Research Australia, Nadia Levin spoke with Australian Health Journal about the following:
– Current medical research and development landscape in Australia
– Investment required to support the Health and Medical Research and Innovation pipeline
– The National Medical Products Industry Plan and its impact on the Australian economy
– The Health and Medical Research WorkforceIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.